Wedbush Reiterates Outperform Rating for Perspective Therapeutics (NYSE:CATX)
Perspective Therapeutics (NYSE:CATX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $11.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 187.96% from the stock’s current price. Several other […]
Perspective Therapeutics (NYSE:CATX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $11.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 187.96% from the stock’s current price. Several other […]
